ONE MONTH INJECTION FOR OSTEOPOROSIS

描述(改编自申请)：骨质疏松症和Paget‘s 疾病是骨骼疾病中最普遍的两种疾病。 美国2400多万人患有骨质疏松症 它的受害者现在每年估计要花费70亿到100亿美元。 骨质疏松症每年导致130多万人骨折。Paget‘s 疾病进展缓慢，可导致疼痛、溶骨性损害和 骨骼结构的严重畸形。骨质疏松症与Paget病 涉及骨骼生长和吸收的不平衡；这两种疾病 可以用被称为多肽激素的多肽激素有效地治疗 降钙素。对类固醇激素副作用的关注 骨质疏松症的治疗迫使临床医生开降钙素 在欧洲，现在又在美国。给患者注射多肽 每日皮下或肌肉间注射。这种做法是 因不便和发病率高而被患者接受程度低 不良反应。每月持续注射鲑鱼降钙素 可以提供更具吸引力的效率和 比现有的任何一种管理方法都要方便。 建议的商业应用： 潜在的商业应用程序不可用。

DESCRIPTION (Adapted from the application): Osteoporosis and Paget's disease are two of the most widespread disorders of bone disease. Osteoporosis affects more than 24 million people in the United States and its victims now cost an estimated $7 to $10 billion per year. Osteoporosis contributes to over 1.3 million fractures per year. Paget's disease progresses slowly and can cause pain, osteolytic lesions, and gross deformities of bone structure. Osteoporosis and Paget's disease involve an imbalance between bone growth and resorption; both diseases can be treated effectively with polypeptide hormones known as calcitonins. Concern about the side effects of steroid hormones for the treatment of osteoporosis is forcing clinicians to prescribe calcitonin in Europe and now in the United States. The polypeptide is administered by daily subcutaneous or intermuscular injection. This practice is poorly accepted by patients because of inconvenience and high incidence of adverse reactions. A monthly sustained injection of salmon calcitonin could provide a much more attractive combination of efficiency and convenience than either of the existing methods of administration. PROPOSED COMMERCIAL APPLICATION: Potential commercial application not available.